Itulazax

Betula verrucosa, the active ingredient in Itulazax, is an allergen extract presented as a sublingual preparation for sublingual use. It is indicated for the treatment of allergic rhinitis and allergic conjunctivitis caused by birch pollen in sensitised individuals.

GNH USA supplies Itulazax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality standards and provides regulatory documentation for export to EU and other markets. Customers benefit from reliable lead times and dedicated technical support throughout the procurement process.

Itulazax is used in allergen immunotherapy targeting birch pollen–induced respiratory allergy. - Allergic rhinitis due to birch pollen: reduces nasal congestion, sneezing and itching. - Allergic conjunctivitis due to birch pollen: alleviates ocular redness, tearing and itching. - Seasonal birch pollen allergy: improves overall tolerance and may decrease the need for rescue antihistamines.

Sublingual administration of Itulazax may be associated with local and systemic adverse reactions.

Common Side Effects: - Mild oral itching or tingling: transient sensation on the tongue or palate. - Transient throat irritation: mild discomfort that resolves without treatment. - Nasal congestion: temporary increase in nasal blockage. - Mild headache: occasional tension‑type headache.

Serious or Rare Side Effects: - Anaphylaxis: severe systemic allergic reaction requiring immediate medical attention. - Angioedema: swelling of lips, tongue or airway that may compromise breathing. - Severe asthma exacerbation: sudden worsening of bronchospasm in asthmatic patients.

Prior to prescribing Itulazax, clinicians should consider several safety and handling precautions. - Allergy testing: confirm sensitisation to Betula verrucosa before initiation. - Medical history: assess for uncontrolled asthma or severe cardiovascular disease. - Concurrent immunotherapy: avoid simultaneous use of other allergen extracts without specialist guidance. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as data are limited. - Monitoring: observe patients for at least 30 minutes after the first dose for systemic reactions. - Store at ambient temperature: keep below 25 °C, in original container, protected from moisture and direct sunlight.

Itulazax may interact with medications that influence immune response or increase the risk of allergic reactions.

Major Interactions (Avoid): - Beta‑blockers: may mask symptoms of anaphylaxis and complicate emergency treatment. - ACE inhibitors: can potentiate angioedema risk when combined with allergen exposure.

Moderate Interactions (Monitor Closely): - Antihistamines: may reduce perceived efficacy of sublingual immunotherapy; timing adjustments may be needed. - Corticosteroids: systemic steroids can alter immune modulation; monitor clinical response. - Other allergen extracts: concurrent use may increase cumulative allergen load; coordinate with allergist.